MedPath

Achieving Nutritional Adequacy Of Vitamin K With An Egg/Plant-Based Food Pairing

Not Applicable
Completed
Conditions
Nutritional Requirements
Registration Number
NCT04286321
Lead Sponsor
Ohio State University
Brief Summary

Malnutrition of the fat-soluble nutrient vitamin K (phylloquinone; PQ) is problematic. Since PQ is rich in plant foods (e.g. spinach) that are mostly absent of accessible lipid, dietary patterns that can potentiate PQ bioavailability by pairing vegetables with lipid-rich foods have been emphasized. The purpose of this study is to use deuterium-labeled spinach (containing stable isotopes of PQ) to validate eggs as a dietary tool to improve PQ bioavailability directly from a model plant food, and hence achieve nutrient adequacy. It is expected that compared with deuterium-labeled spinach alone, co-ingestion of eggs will increase plasma bioavailability of spinach-derived deuterium-labeled PQ without affecting time to maximal concentrations or half-lives. Further, phospholipid-rich egg yolk lipid will enhance nutrient bioavailability compared with vegetable oil. The outcomes will serve as the foundation for easy-to-implement message of public health importance in support of whole eggs and egg whites as part of a plant-based dietary pattern.

Detailed Description

In the US, 43-63% of men and women do not meet recommended intakes for PQ. Dietary recommendations strongly encourage a diet rich in fruits and vegetables to meet dietary PQ requirements. However, PQ bioavailability from most plant foods is quite poor, thereby emphasizing a need for effective food pairings that can enhance the absorption and promote adequate status of these health-promoting nutrients. The objective of this study is to demonstrate that an effective food pairing of spinach with phospholipid lipid-rich eggs promotes intestinal absorption of spinach-derived PQ, and hence achieve nutrient adequacy. Our hypothesis is that the bioavailability of PQ from deuterium-labeled spinach will be potentiated by egg intake in a dose-dependent manner by increasing their secretion in intestinal-derived chylomicrons. Furthermore, phospholipid-rich whole eggs will enhance spinach-derived PQ bioavailability compared with vegetable oil, and will be most functionally responsible for the benefits of eggs to enhance nutrient absorption. Additionally, egg whites will more greatly promote nutrient bioaccessibility compared with spinach alone.

To test this, our specific aim is to assess egg-mediated improvements in PQ bioavailability by conducting a cross-over pharmacokinetic study in healthy men and women. In Study Arms 1-4, participants will ingest deuterium-labeled spinach (containing 500 μg PQ) with 0, 1, 2, or 3 hardboiled eggs (containing 0, 4.8, 9.6, or 14.4 g total fat, respectively). In Study Arm 5, participants will ingest spinach alone followed by 1 egg 3-hours later. In Study Arm 6, participants will ingest spinach with 1 egg followed by another egg 3-hours later. In Study Arm 7, participants will ingest spinach with two egg whites. In Study Arm 8, participants will ingest spinach with 9.6 grams of vegetable oil. Thus, Study Arms 1-4 will test the dose-dependent effects of eggs on PQ bioavailability, Study Arms 5-6 (with comparison to Study Arms 1 and 2) will test the 'timing'-dependent effects of eggs on PQ bioavailability, and Study Arms 7-8 will test the matrix effect on PQ bioavailability. Eucaloric diets will be controlled for PQ intakes for 3 d prior to and during the initial 24 h of each trial to minimize heterogeneity of pharmacokinetic responses. Spinach-derived deuterium-labeled PQ will be measured in plasma and isolated chylomicrons collected at timed intervals from 0-72 h post-meal ingestion, and biomarkers of antioxidant status and oxidative distress will be assessed at baseline (0 h) of each trial. Outcomes from this study are expected to establish that egg lipids substantially enhance plant-derived PQ bioavailability (based on AUC0-72 h, Cmax, and % estimated absorption) independent of any changes in oxidative distress.

The rationale for this study is that, by establishing the efficacy of eggs and egg yolk lipids to potentiate plant-derived fat-soluble nutrient bioavailability, a strong framework will exist for an easily implementable health-promoting food pairing strategy to overcome malnutrition of PQ.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Body Mass Index (BMI) = 19-25 kg/m2
  • Normolipidemic (total cholesterol <240 mg/dL; triglyceride <150 mg/dL)
  • Fasting glucose <100 mg/dL
  • Normal hematocrit level (41%-50% for men and 36%-48% for women)
  • Normal hemoglobin level (13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women)
  • No use of dietary supplements for >1 month
  • No use of medications that affect lipid or glucose metabolism
  • Non-smoker
  • No history of gastrointestinal disorders
Exclusion Criteria
  • Egg allergy
  • Alcohol intake > 2 drinks per day
  • Aerobic activity >7 h/wk
  • Body mass change >2 kg in the past 1 month
  • Women who are pregnant, lactating, or initiated or changed birth control in the past 3 month
  • Vegetarian

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Vitamin K Bioavailability0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach

Area under the curve of deuterium-labeled phylloquinone

Secondary Outcome Measures
NameTimeMethod
Vitamin K Tmax0-72 hours post-ingestion of spinach

Time to reach maximum plasma concentration of deuterium-labeled phylloquinone

Chylomicron Vitamin K0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach

Deuterium-labeled phylloquinone concentration in chylomicron

Estimated Absorption (%Dose) of Vitamin K0-72 hours post-ingestion of spinach

Absorption of deuterium-labeled phylloquinone

Vitamin K Cmax0-72 hours post-ingestion of spinach

Maximum plasma concentration of deuterium-labeled phylloquinone

Elimination Rate of Vitamin K0-72 hours post-ingestion of spinach

Rate of plasma elimination of deuterium-labeled phylloquinone

Trial Locations

Locations (1)

Bruno Lab

🇺🇸

Columbus, Ohio, United States

Bruno Lab
🇺🇸Columbus, Ohio, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.